Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 151 to 200 of 1866

TitleReference numberPublishedLast updated
Babies, children and young people's experience of healthcareNG204
Balloon angioplasty of pulmonary vein stenosis in infantsIPG75
Balloon angioplasty with or without stenting for coarctation or recoarctation of the aorta in adults and childrenIPG74
Balloon catheter dilation of paranasal sinus ostia for chronic sinusitisIPG273
Balloon catheter insertion for Bartholin's cyst or abscessIPG323
Balloon cryoablation for Barrett's oesophagusIPG682
Balloon cryoablation for squamous dysplasia of the oesophagusIPG683
Balloon dilatation of pulmonary valve stenosisIPG67
Balloon dilatation of systemic to pulmonary arterial shunts in childrenIPG77
Balloon dilatation with or without stenting for pulmonary artery or non-valvar right ventricular outflow tract obstruction in childrenIPG76
Balloon dilation for chronic eustachian tube dysfunctionIPG665
Balloon kyphoplasty for vertebral compression fracturesIPG166
Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertensionIPG554
Balloon valvuloplasty for aortic valve stenosis in adults and childrenIPG78
Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal)TA732
Baricitinib for moderate to severe rheumatoid arthritisTA466
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)TA982
Baricitinib for treating moderate to severe atopic dermatitisTA681
Baricitinib for treating severe alopecia areataTA926
Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence after colon and rectum removalIPG642
Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and managementNG231
Bedwetting in under 19sCG111
Behaviour change: digital and mobile health interventionsNG183
Behaviour change: general approachesPH6
Behaviour change: individual approachesPH49
Belimumab for treating active autoantibody-positive systemic lupus erythematosusTA752
Belimumab for treating lupus nephritis (terminated appraisal)TA806
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and overTA949
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemiaTA694
Bendamustine for the first-line treatment of chronic lymphocytic leukaemiaTA216
Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal)TA206
Benralizumab for treating severe eosinophilic asthmaTA565
Berotralstat for preventing recurrent attacks of hereditary angioedemaTA738
Beta interferons and glatiramer acetate for treating multiple sclerosisTA527
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinomaTA178
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancerTA118
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal)TA148
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)TA436
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)TA353
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancerTA214
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancerTA263
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancerTA285
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancerTA212
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancerTA284
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)TA560
Bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapseIPG669
Bimekizumab for treating active psoriatic arthritisTA916
Bimekizumab for treating axial spondyloarthritisTA918
Bimekizumab for treating moderate to severe plaque psoriasisTA723
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancerIPG752

Results per page

  1. 10
  2. 25
  3. 50
  4. All